Daxor Corporation Announces Major Research Studies
Major Research Presented and Published at the Critical Care Congress in Phoenix, Arizona, Utilizing the Daxor BVA-100 Blood Volume Analyzer
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 01/30/15 -- Daxor Corporation (NYSE MKT: DXR) -- A study on 50 patients with severe sepsis published in the journal Critical Care Medicine, Volume 42, No. 12, December 2014, entitled Central Venous Pressure: Is It An Accurate Reflection of Intravascular Volume Status? analyzed whether central venous pressure is an accurate reflection of intravascular blood volume status. The authors of the study from the University of Hawaii, Drs. Catherine Lindsay McKnight, Mihae Yu, et al., utilizing the BVA-100 blood volume analyzer, found 17% of the patients who developed a normal or high central venous pressure can still be hypovolemic (low blood volume) and, therefore, would be under treated utilizing this common procedure.
Central venous pressure is a commonly used semi-invasive procedure to treat septic patients in intensive care units. Septic patients commonly have death rates ranging between 20 to 40% because of the collapse of their circulation. Correct volume replacement is essential to avoid inadequate treatment as well as to avoid over treatment with saline which may flood the lungs with sterile salt water. Direct blood volume measurement with the BVA-100 blood volume analyzer avoids these complications.
Another study titled Persistently High albumin Leak is Associated With Mortality by Scott Harvey, Mihae Yu, et al., also appearing in the journal Critical Care Medicine, and also involving 50 people, demonstrated that patients with a high albumin leak have an increased mortality rate. Significantly higher death rates were observed in patients on days 3 to 5 of their admission to the intensive care unit. The BVA-100 was utilized in this study also.
Dr. Mihae Yu, senior author of these studies has previously published a landmark study in the journal Shock in 2011. This prospective study of 100 patients with sepsis compared patients treated with blood volume measurements vs. patients treated without this data, there was a 24% death rate with patients treated with standard procedures such as pulmonary artery catheterization (PAC) vs. an 8% death rate in patients treated utilizing blood volume measurement for goal directed therapy. This was a remarkable difference in the treatment of sepsis, which has not only a high death rate, but significant morbidity such as permanent brain damage in patients who survive their time in the intensive care unit.
Daxor Corporation manufactures and markets the only FDA approved Blood Volume Analyzer, the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's BVA-100 Blood Volume Analyzer, visit Daxor's website at .
Daxor Contact Information:
Michael Feldschuh
Executive Vice President
212-330-8500
or
Diane Meegan
Corporate Secretary
212-330-8512
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.01.2015 - 13:30 Uhr
Sprache: Deutsch
News-ID 368108
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Health & Nutrition
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Daxor Corporation Announces Major Research Studies"
steht unter der journalistisch-redaktionellen Verantwortung von
Daxor Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
